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Most clinicians relate parkinsonism and
dyskinesia directly to acute and tardive
drug-induced movement disorders. How-
ever, parkinsonism and dyskinesia are
also present in antipsychotic-naïve patients
with psychotic disorders. In this paper,
we want to highlight the clinical value
of these spontaneous movement disor-
ders and want to discuss the concept of
“non-mental signs.”
ACUTE DRUG-INDUCED MOVEMENT
DISORDERS
Acute drug-induced movement disorders,
such as acute dystonia, parkinsonism, and
akathisia, are very common side effects
of dopamine blocking agents. A causal
relationship between these movement
disorders and antipsychotics is beyond
any doubt if (i) antipsychotic-naïve psy-
chotic patients without movement disor-
ders receive antipsychotics and develop
these side effects, (ii) they disappear after
dose reduction or cessation of the antipsy-
chotics, and (iii) this on–off mechanism
can be repeated.
TARDIVE SYNDROMES
The relationship between tardive syn-
dromes and antipsychotics is far more
complex because they start after months
to years of treatment with antipsychotics
and can also be suppressed by antipsy-
chotics. Tardive suggests drug induced, and
also spontaneous hyperkinetic dyskinesias,
such as “grimacing” and “irregular move-
ments of tongue and lips”(and also parkin-
sonism), are prevalent in antipsychotic-
naïve psychotic patients and have been
described by Kraepelin and Bleuler more
than a 100 years ago (1).
In patients with long-term use
of antipsychotics, there is no test to
differentiate between drug-induced tardive
and spontaneous movement disorders. The
prevalence of drug-induced tardive dyski-
nesia is substantial and increases with age,
the same counts for spontaneous move-
ment disorders such as dyskinesia, bradyki-
nesia, and soft neurological signs related to
schizophrenia (2–15). Also, a meta-analysis
showed that in antipsychotic-naïve patients
with schizophrenia the risk of dyskinesia
and parkinsonism are three and five times
higher than in healthy controls, respec-
tively (16). Furthermore, another study
in antipsychotic-naïve patients showed a
prevalence of dyskinesia and parkinsonism
of 13 and 18%, respectively, with the use
of clinical rating scales, which increased to
20 and 28%, respectively, with the use of
instrumental assessment (17).
On the other hand, several findings sug-
gest a direct relationship between antipsy-
chotics and tardive dyskinesia. First, non-
psychiatric patients may also develop tar-
dive dyskinesia after long-term use of
dopamine blocking agents, e.g., long-term
use of metoclopramide to treat nausea,
or antipsychotics for insomnia (18, 19).
Furthermore, in older patients receiving
first-generation antipsychotics for the first
time the yearly incidence of tardive dysk-
inesia is extremely high, over 20%, which
is much higher than the incidence of
spontaneous dyskinetic movement in older
patients (12, 13). Also, tardive dyskinesia
may disappear after cessation of antipsy-
chotics or after a switch to clozapine.
These findings suggest a direct relation-
ship between antipsychotics and tardive
dyskinesia.
Based on the studies mentioned above,
it is clear that the assumption that antipsy-
chotics are responsible for tardive dyskine-
sia is at least incomplete. Indeed, move-
ment disorders can be considered an
intrinsic feature of the disease process
and implicate dysfunction in cortical–basal
ganglia-cortical circuitry (11). The role of
the antipsychotics may be modification of
the disease-based motor disorder and anti-
psychotics can both improve and unmask
primary motor abnormalities (10).
The clinical importance of spontaneous
movement disorders is also emphasized
by the relationship between spontaneous
parkinsonism and cognitive dysfunction.
In a prospective study in antipsychotic-
naïve patients with first-episode psychosis,
spontaneous parkinsonism at baseline
showed high 6-month predictive values for
cognitive impairment (9).
PATHOPHYSIOLOGY
The pathogenesis of tardive dyskinesia
remains unresolved. Several hypotheses
have been proposed such as dopamine
2 (D2)-receptor hypersensitivity, striatal
neurodegeneration, maladaptive synaptic
plasticity, and enhanced serotonin 2 (5-
HT2)-receptor signaling and recently up
regulation of striatal D3 receptors had
been suggested in a primate model (20).
Although none of these models have
been confirmed sufficiently they have in
common the disturbance of the bal-
ance in the motor circuit of the basal
ganglia in which dopamine plays a cen-
tral role. The dopamine (and possibly
also the acetylcholine) dysregulation in the
basal ganglia-thalamo-cortical loops may
result in hyper or hypokinetic movements
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whereas dopamine dysregulation in other
brain areas may result in the development
of psychosis (21).
Another model is based on synap-
tic dysregulations in which the core
hypothesis is that non-functional astro-
cytic receptors may cause an uncon-
strained synaptic information flux, such
that glia lose their modulatory function
in glial–neuronal interaction (tripartite
synapses) (22). Dysregulation of tripar-
tite synapses would occur with dopamine
synapses throughout the brain and may
be related to both motoric and mental
symptoms.
CLINICAL RELEVANCE
The clinical relevance for measuring dyski-
nesia and/or parkinsonism in first-episode
psychotic disorders is based on several
follow-up studies showing that they pre-
dict poor prognosis, increased cognitive
impairment, poorer response to antipsy-
chotics, and an increased risk for drug-
induced movement disorders (9, 11, 23).
Also, in individuals at ultra-high risk
for psychosis (UHR group) the assessment
of spontaneous movement disorders may
be highly relevant. Several studies suggest
that subtle abnormal movements are pre-
dictive for conversion to psychosis later.
The current screening strategy focuses on
mental symptoms and has a limited con-
version rate to psychosis, around 20–40%,
giving to many false positives. It could
be that adding measurement of move-
ment disorders to the screening strategy
will reduce the number of false positives.
Indeed, studies show (i) more abnormal
movements in the UHR group than in the
control group, (ii) a relationship between
the severity of the abnormal movements
and the severity of prodromal signs (posi-
tive, negative, and total) at baseline, (iii) a
relationship between an increase in sever-
ity of the abnormal movements with an
increase of prodromal signs during follow-
up, and (iv) a higher risk to convert to
psychosis at follow-up in the UHR groups
with abnormal movements at baseline than
those without (24, 25).
Detection of those in the UHR group
who will convert to psychosis is rele-
vant as a meta-analysis showed the effec-
tiveness of some interventions to pre-
vent or postpone a first-episode of psy-
chosis (26).
RELATIONSHIP BETWEEN MOVEMENT,
COGNITIVE, AND EMOTIONAL
DISORDERS
Obeso et al. describe that the basal ganglia
are intimately connected with the cortex
through several segregated but parallel
loops. These loops are subdivided into
motor, associative (cognitive), and limbic
(emotional) domains and are related to the
control of movement, behavior and cog-
nition, and reward and emotions, respec-
tively. When one or more of these circuits
become dysfunctional they can generate
movement disorders, behavioral, cognitive
abnormalities, or mood changes. They sug-
gest, for example that the combination of
nigrostriatal denervation and dopaminer-
gic drugs, as seen in Parkinson’s disease,
may induce behavioral disorders such as
impulse control disorders and that this may
be the behavioral counterpart of hyper-
kinetic disorders such as dyskinesia (27).
Similar with this idea is the concept that
dysregulation of dopaminergic activity in
dopaminergic related brain areas lead to
positive and negative symptoms in psy-
chotic disorders and that these symptoms
are the behavioral counterpart of dyski-
nesia and bradykinesia, respectively. It has
been suggested that psychotic patients with
abnormal movements, compared to those
without, have a more severely dysregu-
lated dopamine system (28). This may
explain the clustering of abnormal move-
ments with cognitive and negative symp-
toms and the relationship with poor prog-
nosis. Also, a correlation has been found
between tardive dyskinesia and cognitive
symptoms (29). It could be that drug-
induced movement disorders are related to
a more vulnerable dopamine system and
subsequently to an increased risk for dysk-
inesia and negative and cognitive symp-
toms. In line with the vulnerability con-
cept is the relationship found between early
extrapyramidal symptoms such as parkin-
sonism and an increased risk for develop-
ing tardive dyskinesia in the future (30, 31).
However, the underlying dysfunction(s)
that provoke(s) spontaneous movement
abnormalities, tardive dyskinesia, cogni-
tive impairment, negative symptoms, and
emotional disturbances remains unclear.
It is unlikely that one neurotransmitter,
i.e., dopamine is responsible. Although,
dysfunction of the modulatory activity
of dopamine plays an important role
in the clinical manifestations mentioned
above, also acetylcholine, which is released
across the entire striatal network by stri-
atal cholinergic interneurons, has neuro-
modulatory properties in the basal ganglia.
Furthermore, other neurotransmitters are
involved, such as glutamatergic inputs from
the cerebral cortex and thalamus to striatal
spiny projection neurons (21).
NON-MENTAL SIGNS
Based on the presence of motor, associative
(cognitive), and limbic (emotional) loops
in the basal ganglia, we want to introduce
the concept of non-mental signs (dyski-
nesia and parkinsonism) in psychotic dis-
orders. This concept is the equivalent of
non-motor signs (mood disorders, apa-
thy, anxiety, etc.) in Parkinson’s disease
(32). The severity of non-mental signs may
have a direct relationship with the sever-
ity of dysregulation of the dopamine sys-
tem. An advantage of non-mental signs is
the possibility to measure them objectively
and several research groups have developed
instruments to measure these non-mental
signs instrumentally. Instrumental assess-
ment of movement disorders is sensitive,
valid, and reliable and a motor test battery
that will quantify the main motor func-
tions has been suggested (33–38). In addi-
tion, instrumental measurement can also
detect subclinical movement abnormalities
and these assessments may be used to pre-
dict the course of a (pre)psychotic disor-
der and can be used to develop preventive
strategies.
In conclusion, we suggest classifying
movement disorders in psychotic disorders
or in UHR groups as non-mental signs.
Instrumental measurements of these non-
mental signs are objective and have clin-
ical implications for prognosis, diagnosis,
and treatment of psychotic disorders. In
UHR groups adding non-mental signs to
the screening strategy may reduce the num-
ber of false positives. Non-mental signs
could become one of the first biomarkers
in psychiatric screening programs.
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